The TAU project (Taupatías) aims to develop innovative biomarkers based on monoclonal antibodies for the early diagnosis of neurodegenerative diseases such as Alzheimers Disease and Frontotemporal Dementia. These pathologies, known as tauopathies, are associated with the abnormal accumulation of the tau protein in the brain, leading to neuronal degeneration and progressive cognitive decline. The use of monoclonal antibodies will allow for the precise and specific identification of tau protein alterations, thus facilitating the early detection of these diseases.
Additionally, the project will include the development of a clinical decision support system, based on the integration of biomedical data and advanced analysis algorithms, to assist healthcare professionals in the diagnostic process and in making therapeutic decisions. This system will allow a more accurate evaluation of the risk of developing tauopathy and help monitor the progression of the disease in diagnosed patients. With TAUPATÍAS, significant progress is expected in the early detection of these pathologies, offering new tools for early intervention and clinical follow-up, with the goal of improving patients quality of life and optimizing the management of neurodegenerative diseases.
